On October 2, 2020, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Opdivo (nivolumab). This significant regulatory action, identified as BLA 125554 S-89, was granted based on new efficacy data submitted by the drug's sponsor, Bristol Myers Squibb.
Background
Nivolumab, commercially known as Opdivo, is a well-established immunotherapy agent developed and marketed by Bristol Myers Squibb. It belongs to a class of drugs that help the body's immune system fight cancer. Since its initial approvals, Opdivo has become a cornerstone in the treatment of various advanced cancers, often used alone or in combination with other therapies. Supplemental applications for efficacy, such as this one, are submitted when new clinical data demonstrate additional benefits or expand the drug's utility. These applications typically lead to updates in the drug's official label, reflecting new indications, expanded patient populations, or revised treatment guidelines based on proven effectiveness.
What this means
The FDA's approval of this supplemental application for Opdivo (nivolumab) confirms that new clinical evidence has successfully demonstrated additional efficacy for the drug. While the specific details regarding the new indication or patient population are not provided in this regulatory notice, such approvals are crucial for expanding treatment options. This allows healthcare professionals to consider nivolumab for a broader spectrum of patients or conditions, or to utilize it within new treatment protocols, all supported by the validated efficacy data reviewed by the FDA. This type of approval underscores the ongoing research and development efforts to maximize the therapeutic potential of existing oncology treatments and provide more options for patients.
Source
The information regarding this regulatory event was obtained from the official website of the U.S. Food and Drug Administration (FDA), specifically within the agency's Drugs@FDA database. The supplemental application for Opdivo (nivolumab), identified by its application number BLA 125554 S-89, received approval on October 2, 2020. Further details can be verified on accessdata.fda.gov.